The pharmaceutical community is abuzz with anticipation surrounding retatrutide, a novel dual GIP and GLP-1 agonist that’s demonstrating significant potential in clinical trials for treating obesity. Unlike some existing weight loss solutions, retatrutide appears to deliver a greater substantial loss in body weight and benefit metabolic function,